SHJBF Stock - Shanghai Junshi Biosciences Co., Ltd.
Unlock GoAI Insights for SHJBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.95B | $1.50B | $1.45B | $4.02B | $1.59B |
| Gross Profit | $1.45B | $835.26M | $927.21M | $2.77B | $1.22B |
| Gross Margin | 74.4% | 55.6% | 63.8% | 68.7% | 76.6% |
| Operating Income | $-1,300,202,000 | $-2,452,016,000 | $-2,751,182,000 | $-592,707,000 | $-1,668,418,000 |
| Net Income | $-1,282,398,000 | $-2,281,624,000 | $-2,386,067,000 | $-718,557,000 | $-1,665,639,000 |
| Net Margin | -65.8% | -151.9% | -164.2% | -17.9% | -104.4% |
| EPS | $-1.30 | $-2.32 | $-2.60 | $-0.81 | $-2.02 |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Visit WebsiteEarnings History & Surprises
SHJBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 28, 2025 | — | $-0.03 | — | — |
Q3 2025 | Aug 26, 2025 | — | $-0.03 | — | — |
Q2 2025 | Apr 25, 2025 | — | $-0.03 | — | — |
Q1 2025 | Mar 27, 2025 | — | — | — | — |
Q4 2024 | Oct 29, 2024 | — | $-0.04 | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.05 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.04 | — | — |
Q1 2024 | Mar 29, 2024 | — | $-0.12 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.06 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.07 | — | — |
Q1 2023 | Mar 30, 2023 | $-0.10 | $-0.08 | +16.4% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.09 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.07 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.06 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.07 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.06 | — | — |
Q1 2021 | Mar 30, 2021 | — | $0.07 | — | — |
Latest News
Frequently Asked Questions about SHJBF
What is SHJBF's current stock price?
What is the analyst price target for SHJBF?
What sector is Shanghai Junshi Biosciences Co., Ltd. in?
What is SHJBF's market cap?
Does SHJBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SHJBF for comparison